Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Ratio: 2009-2025

Historic Equity Ratio for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Sep 2025 value amounting to 0.46.

  • Madrigal Pharmaceuticals' Equity Ratio fell 36.57% to 0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46, marking a year-over-year decrease of 36.57%. This contributed to the annual value of 0.72 for FY2024, which is 14.38% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Equity Ratio stood at 0.46 for Q3 2025, which was down 33.00% from 0.69 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Equity Ratio's 5-year high stood at 0.84 during Q1 2021, with a 5-year trough of 0.07 in Q3 2022.
  • In the last 3 years, Madrigal Pharmaceuticals' Equity Ratio had a median value of 0.69 in 2025 and averaged 0.58.
  • In the last 5 years, Madrigal Pharmaceuticals' Equity Ratio crashed by 91.28% in 2022 and then surged by 674.46% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.72 in 2021, then declined by 24.12% to 0.54 in 2022, then rose by 16.23% to 0.63 in 2023, then rose by 14.38% to 0.72 in 2024, then slumped by 36.57% to 0.46 in 2025.
  • Its Equity Ratio stands at 0.46 for Q3 2025, versus 0.69 for Q2 2025 and 0.71 for Q1 2025.